Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings ...
Scientists have zeroed in on a critical weak spot behind a rare but devastating brain autoimmune disorder often known as ...
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its ...
Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...
MIRA Pharmaceuticals has completed dosing in its Phase I clinical trial of Ketamir-2, the company’s selective oral N-methyl-D-aspartate (NMDA) receptor modulator, assessing its safety, tolerability, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results